Dipeptidylpeptidase (DPP)-4 inhibitor therapy increases circulating levels of anti-inflammatory soluble frizzle receptor protein (sFRP)-5 which is decreased in severe COVID-19 disease
二肽基肽酶 (DPP)-4 抑制剂疗法可提高抗炎可溶性卷曲受体蛋白 (sFRP)-5 的循环水平，而重症 COVID-19 疾病中该蛋白的水平会降低
期刊:Scientific Reports
影响因子:3.8
doi:10.1038/s41598-022-18354-x
Juliane Brandes #, Isabelle Zobel #, Nathalie Rohmann, Kristina Schlicht, Corinna Geisler, Katharina Hartmann, Kathrin Türk, Witigo von Schönfels, Jan Beckmann, Florian Tran, Matthias Laudes
